Mereo Biopharma Group Plc ADR [NASDAQ: MREO] closed the trading session at $2.51.
The stocks have a year to date performance of -28.29 percent and weekly performance of 2.45 percent. The stock has been moved at -43.34 percent over the last six months. The stock has performed -20.57 percent around the most recent 30 days and changed -30.85 percent over the most recent 3-months.
If compared to the average trading volume of 1.21M shares, MREO reached to a volume of 3938624 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Mereo Biopharma Group Plc ADR [MREO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MREO shares is $7.34 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MREO stock is a recommendation set at 1.12. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Mereo Biopharma Group Plc ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 06, 2024. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on June 13, 2024, representing the official price target for Mereo Biopharma Group Plc ADR stock. Previously, the target price had yet another raise to $4, while BTIG Research analysts kept a Buy rating on MREO stock.
The Average True Range (ATR) for Mereo Biopharma Group Plc ADR is set at 0.17 The Price to Book ratio for the last quarter was 5.35, with the Price to Cash per share for the same quarter was set at 0.52.
MREO stock trade performance evaluation
Mereo Biopharma Group Plc ADR [MREO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.45. With this latest performance, MREO shares dropped by -20.57% in over the last four-week period, additionally sinking by -43.34% over the last 6 months – not to mention a drop of -34.97% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MREO stock in for the last two-week period is set at 35.92, with the RSI for the last a single of trading hit 37.26, and the three-weeks RSI is set at 36.60 for Mereo Biopharma Group Plc ADR [MREO]. The present Moving Average for the last 50 days of trading for this stock 3.06, while it was recorded at 2.45 for the last single week of trading.
Mereo Biopharma Group Plc ADR [MREO]: An insightful look at the core fundamentals
Mereo Biopharma Group Plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.10 and a Current Ratio set at 6.10.
Earnings per share (EPS) analysis for Mereo Biopharma Group Plc ADR [MREO] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MREO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Mereo Biopharma Group Plc ADR go to 6.69%.
Mereo Biopharma Group Plc ADR [MREO]: Institutional Ownership
The top three institutional holders of MREO stocks are: RUBRIC CAPITAL MANAGEMENT LP with ownership of 15.31 million shares, which is approximately 2.1506%. ADAGE CAPITAL PARTNERS GP, L.L.C., holding 11.79 million shares of the stock with an approximate value of $$42.45 million in MREO stocks shares; and ADAGE CAPITAL PARTNERS GP, L.L.C., currently with $$33.42 million in MREO stock with ownership which is approximately 1.3043%.
